Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One common respiratory ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

Respiratory syncytial virus (RSV) is a common virus that usually causes mild, cold-like symptoms. You may have heard of ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

respiratory syncytial virus (RSV) vaccination among older adults was associated with a substantially reduced risk of hospitalization, a test-negative, case-control study indicated. In adults 60 ...

This lack of testing amplifies the misdiagnosis of RSV, as its symptoms are so similar to other, more common respiratory viruses like flu. A lack of recognition can also be seen in older adults ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial ...

According to the U.S. Centers for Disease Control and Prevention, RSV results in 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths of adults 67 and older each year. "We view this as a ...

RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines available to prevent disease caused by RSV in adults ...